CoChat
Sign Up
Cited by 206Chronic Obstructive Pulmonary Disease (COPD) ResearchAsthma and respiratory diseasesAdvanced Chemical Sensor Technologies

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Exhaled nitric oxide from lung periphery is increased in COPD

Open access
Brindicci, C., Ito, K., Resta, O., Pride, N. B., Barnes, P. J., Kharitonov, S. A.·2005·European Respiratory Journal
DOI 10.1183/09031936.04.00125304
Open this paper in CoChat — free accountOpen PDF

Abstract

Single constant flow exhaled nitric oxide (eNO) cannot distinguish between the sources of NO. The present study measured eNO at multiple expired flows (MEFeNO) to partition NO into alveolar (Calv,NO) and bronchial (Jaw,NO) fractions to investigate peripheral lung contribution to eNO in chronic obstructive lung disease (COPD). MEFeNO were made in 81 subjects including 18 nonsmokers, 16 smokers and 47 COPD patients of different severity by the classification of the Global Initiative for Chronic Obstructive Lung Disease (GOLD): 0 (n = 14), 1 (n = 7), 2 (n = 11), 3 (n = 8) and 4 (n = 7). COPD severity was correlated with an increased Calv,NO regardless of the patient's smoking habit or current treatment. The levels of Calv,NO (in ppb) were 1.4+/-0.09 in nonsmokers, 2.1+/-0.1 in smokers categorised as GOLD stage 0 (smokers-GOLD0), 3.3+/-0.18 in GOLD1-2 and 3.4+/-0.1 in GOLD3-4. Jaw,NO levels (pL x s(-1)) were higher in nonsmokers than smokers-GOLD0 (716.2+/-33.3 versus 464.7+/-41.8), GOLD3-4 (609.4+/-71). Diffusion of NO in the airways (Daw,NO pL x ppb(-1) s(-1)) was higher (p<0.05) in GOLD3-4 than in nonsmokers (15+/-1.2 versus 11+/-0.5) and smokers-GOLD0 (11.6+/-0.5). MEFeNO measurements were reproducible, free from day-to-day and diurnal variation and were not affected by bronchodilators. In conclusion, chronic obstructive pulmonary disease is associated with elevated alveolar nitric oxide. Measurements of nitric oxide at multiple expired flows may be useful in monitoring inflammation and progression of chronic obstructive pulmonary disease, and the response to anti-inflammatory treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/09031936.04.00125304

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 4

  1. 2004, Swiss Med Wkly, 134, 175
  2. 2002, Eur Respir J, 20, 95s
  3. 2002, Eur Respir J, 20, 174s
  4. 1998, Mod Pathol, 11, 648

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Brindicci, C., Ito, K., Resta, O., Pride, N. B., Barnes, P. J., & Kharitonov, S. A.
Affiliations
  • Imperial College London (GB)
  • University of Bari Aldo Moro (IT)
Corresponding author
Kharitonov, S. A.
ORCID
Venue
European Respiratory Journal
Publisher
European Respiratory Society (ERS)
Published
2005-07
Volume
26
Issue
1
Pages
52-59
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
DOI
10.1183/09031936.04.00125304
OpenAlex
W2164167422
Cited by
206
References
29
Citations by year
2026: 3 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 4 · 2020: 8 · 2019: 6 · 2018: 11 · 2017: 6 · 2016: 3 · 2015: 9 · 2014: 5 · 2013: 14 · 2012: 14
FWCI
11.90
Type
journal article
Language
en
Open access
Locations
  • European Respiratory Journal (publishedVersion)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Physical Sciences › Engineering › Biomedical Engineering › Advanced Chemical Sensor Technologies
Keywords
exhaled nitric oxide, chronic obstructive pulmonary disease, alveolar nitric oxide, COPD severity, smoking, airway inflammation
MeSH terms
Adult, Aged, Analysis of Variance, Female, Forced Expiratory Volume, Humans, Male, Middle Aged, Nitric Oxide, Probability, Prognosis, Reference Values, Respiratory Function Tests, Sensitivity and Specificity, Severity of Illness Index, Smoking, Cohort Studies, Biomarkers, Case-Control Studies, Risk Assessment, Statistics, Nonparametric, Pulmonary Disease, Chronic Obstructive, Exhalation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review